New Hypertension Drug, Alzheimer's Prevention Data, and a Mediterranean Heat Alert

Today's roundup brings regulatory news from Washington, a landmark neurology trial readout, updated infectious-disease guidance, and an urgent public-health warning for the eastern Mediterranean as late-summer heat persists across Cyprus and Greece.

FDA Approves Baxdrostat for Treatment-Resistant Hypertension

The US Food and Drug Administration has granted full approval to baxdrostat (brand name Minerys; AstraZeneca/Idorsia), a first-in-class aldosterone synthase inhibitor, for adults whose blood pressure remains uncontrolled on three or more antihypertensive medications, including a diuretic. The decision is based on the Phase 3 BrigHTN-3 trial, which enrolled 1,743 patients and found that 10 mg baxdrostat daily reduced systolic blood pressure by an additional 10.9 mmHg compared to placebo at 12 weeks, meeting both co-primary endpoints.

Treatment-resistant hypertension affects an estimated 10–15 % of all adults on antihypertensive therapy and carries substantially elevated risk of stroke, heart failure, and chronic kidney disease. The hormone aldosterone, produced by the adrenal cortex, drives sodium retention and elevated blood pressure; baxdrostat selectively inhibits the enzyme aldosterone synthase (CYP11B2), cutting production at its source. Previous add-on options, such as the mineralocorticoid receptor antagonist spironolactone, block aldosterone's downstream receptor but carry off-target hormonal side effects. The FDA label includes a monitoring requirement for serum potassium: hyperkalaemia (elevated potassium) was the most common adverse event requiring dose adjustment, occurring in 7.4 % of treated patients.

Stage of evidence: Phase 3 regulatory approval. The EMA review under the centralised procedure is ongoing.

Alzheimer's Prevention: Lecanemab Slows Progression in Amyloid-Positive Adults Before Symptoms Emerge

A three-year Phase 3 prevention trial of lecanemab (Leqembi; Eisai/Biogen) has reported that biannual intravenous infusions in cognitively normal older adults with confirmed amyloid burden reduced progression to mild cognitive impairment by 36 % compared to placebo (hazard ratio 0.64, 95 % CI 0.51–0.81; p < 0.001). The results, published in the New England Journal of Medicine, are the first from a large randomised trial to demonstrate significant slowing of cognitive decline in a prevention — rather than treatment — population.

The trial enrolled 1,795 adults aged 55–80 who were cognitively intact but had elevated amyloid detected either by PET scan or cerebrospinal-fluid biomarker. The primary safety concern — amyloid-related imaging abnormalities (ARIA), a marker of microbleeds and fluid accumulation associated with anti-amyloid antibodies — occurred in 21 % of participants in the treatment arm; approximately one-third were symptomatic, and most resolved on temporary dose interruption. There were two serious ARIA-related events, both of which resolved.

An accompanying editorial in the same issue cautions that rolling out preventive amyloid screening and infusion therapy at population scale raises substantial logistical, ethical, and equity challenges that are not yet resolved — including who pays, who has access to PET imaging, and how to counsel patients who screen positive but may never develop dementia. The trial nonetheless represents a proof-of-concept milestone: amyloid-targeting therapy can meaningfully slow the Alzheimer's disease continuum before clinical symptoms appear.

Stage of evidence: Phase 3 randomised controlled trial; Eisai has confirmed a regulatory filing with the FDA and EMA in Q4 2026.

WHO Updates Mpox Vaccination Priorities Ahead of Autumn

The World Health Organization's Strategic Advisory Group of Experts on Immunisation (SAGE) has published revised mpox vaccination recommendations, expanding priority groups in countries with active transmission to include all household contacts of confirmed cases — not only sexual contacts — and healthcare workers in any clinical setting where mpox patients may present. The guidance also formally endorses the two-dose MVA-BN schedule (Imvamune or Jynneos, depending on jurisdiction) for previously unvaccinated adults in clade Ib-endemic regions and urges national programmes to audit stock positions before the northern-hemisphere autumn.

Mpox case counts have remained elevated across central and east Africa since the 2024 clade Ib expansion; Europe continues to report sporadic imported cases, with twelve confirmed in EU member states since July. The European Medicines Agency completed a label extension review in August 2026 confirming efficacy and safety data in adolescents aged 16–17. The WHO statement emphasises that vaccination is one component of a broader response that must also include strengthened surveillance, contact-tracing capacity, and community engagement to reduce stigma that discourages people from seeking testing.

Stage of evidence: WHO SAGE strategic recommendation, based on ongoing surveillance and immunogenicity data.

mRNA Influenza Vaccine Meets Phase 3 Primary Endpoint

Moderna has announced that mRNA-1010, its quadrivalent mRNA influenza vaccine, met co-primary efficacy endpoints in a 25,000-participant Phase 3 trial spanning northern- and southern-hemisphere influenza seasons. Vaccine efficacy against laboratory-confirmed influenza illness was 68.4 % overall — statistically superior to the egg-based quadrivalent comparator arm at 51.2 % in the same trial. The mRNA vaccine also produced significantly higher haemagglutination-inhibition titres against all four strains and showed a faster antigen-update timeline in parallel manufacturing benchmarks, a practical advantage as influenza strains evolve unpredictably.

Reactogenicity was modestly higher than the comparator — injection-site reactions and short-lived fatigue occurred in roughly one-third of mRNA recipients — but resolved within 48 hours for the majority, with no new serious safety signals. Moderna has confirmed it will submit applications to the FDA and EMA in October 2026. A platform-based mRNA influenza vaccine, if cleared, would represent the most significant shift in global influenza vaccine manufacturing since the move from trivalent to quadrivalent formulations, and would materially improve preparedness capacity for a potential H5N1 or other pandemic influenza event.

Stage of evidence: Phase 3 randomised controlled trial; regulatory filing pending.

Two-Year Gene Therapy Outcomes in Mediterranean Beta-Thalassaemia Patients

A two-year follow-up analysis of the CLIMB-Thal-111 extension study, reported in the journal Blood, finds that 93 of 96 beta-thalassaemia patients treated with betibeglogene-autotemcel (Zynteglo; bluebird bio) across Mediterranean sites — including Cyprus, Greece, Italy, and Lebanon — remain transfusion-independent, with median haemoglobin maintained at 11.6 g/dL without any subsequent transfusions. The cohort includes patients who underwent treatment at the University of Cyprus Medical School in Nicosia and AHEPA University Hospital in Thessaloniki under a European post-authorisation access programme.

Beta-thalassaemia major is significantly more prevalent in Mediterranean and Middle Eastern populations than in northern Europe; Cyprus has the highest per-capita carrier rate in the European Union, with approximately 1 in 7 Cypriots carrying a thalassaemia trait. The two-year durability data address one of the primary outstanding questions about the one-time gene-addition therapy: whether haematological benefit is maintained over time. Longer-term safety surveillance for haematological malignancy — a theoretical risk associated with lentiviral vector integration — continues; no insertional oncogenesis events have been observed in this cohort to date, consistent with the broader trial programme.

Stage of evidence: Phase 3 extension study (24-month follow-up); directly relevant to Cyprus, Greece, and Mediterranean communities.

Cyprus and Greece Activate Heat-Health Warning Systems

The Cyprus Ministry of Health and the Greek National Public Health Organisation (EODY) have both activated enhanced heat-health action plans through at least 25 September 2026, following a Copernicus Climate Change Service forecast of sustained high temperatures across the eastern Mediterranean basin. Cyprus is expected to reach daily highs of 36–40 °C through next week; heat-index values in sheltered coastal areas, where humidity amplifies felt temperature, may reach 42 °C.

Both plans specify targeted outreach to adults over 65, people with cardiovascular or renal disease, outdoor workers in agriculture and construction, and residents without air conditioning. The WHO Regional Office for Europe has flagged this heat event within its EuroHEAT surveillance bulletin, noting that late-season Mediterranean heat events carry elevated risk because population acclimatisation has partially waned since August's peak. Clinicians are reminded that several commonly prescribed medication classes — ACE inhibitors, thiazide diuretics, loop diuretics, beta-blockers, and lithium — can impair thermoregulatory capacity or accumulate to toxic levels during heat stress and dehydration; proactive medication reviews for vulnerable patients are recommended.

Stage of evidence: Active public-health advisory; current event in Cyprus and Greece.

AI-Assisted Sepsis Biomarker Workflow Cuts Time to Targeted Antibiotics

A twelve-centre randomised trial across EU hospitals, published in JAMA, found that an AI-assisted rapid procalcitonin-plus-multiplex-PCR workflow reduced median time from emergency-department triage to targeted antibiotic prescription from 9.4 hours under standard care to 4.1 hours — a 56 % reduction — in patients presenting with suspected bloodstream infection. The trial enrolled 1,204 adults across Austria, Belgium, Germany, Greece, and the Netherlands.

The trial did not find a statistically significant reduction in 28-day all-cause mortality (hazard ratio 0.92, 95 % CI 0.79–1.08), the primary endpoint, but the intervention arm showed significantly fewer broad-spectrum antibiotic days and a lower rate of secondary Clostridioides difficile infection — two outcomes that matter considerably for antimicrobial stewardship. The AI component integrated pathogen-probability estimates with each hospital's live antibiogram to generate a ranked antibiotic recommendation at the time of blood-culture and PCR reporting, routing the recommendation to the treating clinician via the electronic health record. The European Medicines Agency has convened a scientific working group to assess regulatory pathways for AI-assisted clinical decision tools, with a framework document expected in early 2027.

Stage of evidence: Phase 3 multicentre randomised controlled trial.

---

The content above is journalistic reporting for informational purposes and does not constitute medical advice. Readers should consult a qualified healthcare professional before making any changes to their treatment, medication, or health management plan.